Thus, the aim of this study was to investigate the influence of polymorphisms in the drug-metabolizing enzyme genes CYP3A4, CYP3A5, and UGT2B7, as well as the P-glycoprotein transporter gene (ABCB1), on the efficacy, safety, and pharmacokinetics of silodosin in patients with LUTS/BPH. This evidence concerns the gene CYP3A5 and benign prostatic hyperplasia.